The 26 references in paper K. Mukhin Yu., O. Pylaeva A., К. Мухин Ю., О. Пылаева А. (2015) “Применение перампанела (Файкомпы) в лечении эпилепсии (опыт Института детской неврологии и эпилепсии им. Святителя Луки) // PERAMPANEL (FYCOMPA) FOR TREATMENT OF EPILEPSY (EXPERIENCE OF THE SVT. LUKA'S INSTITUTE OF CHILD NEUROLOGY AND EPILEPSY)” / spz:neicon:rjdn:y:2014:i:4:p:14-19

1
Власов П.Н. Клинический случай применения Файкомпы. Эпилепсия и пароксизмальные состояния 2014;(спецвыпуск):5. [Vlasov P.N. Clinical case of application of fycompa. Epilepsy and Paroxysmal States 2014;(special issue):5. (In Russ.)].
(check this in PDF content)
2
Жидкова И.А. Управление нежелательными явлениями, возникающими на фоне приема перампанела. Эпилепсия и пароксизмальные состояния 2014;(спецвыпуск):13–4. [Zhidkova I.A. Management of undesirable phenomena that arise on the background of perampanel intake. Epilepsy and Paroxysmal States 2014;(special issue):13–4. (In Russ.)].
(check this in PDF content)
3
Мухин К.Ю., Пылаева О.А., Миронов М.Б. Применение перампанела у ребенка с резистентной эпилепсией при синдроме Ангельмана. Эпилепсия и пароксизмальные состояния 2014;(спецвыпуск):15. [Mukhin K.Yu., Pylaeva O.A., Mironov M.B. Perampanel for children with resistant epilepsy of the Angelman syndrome. Epilepsy and Paroxysmal States 2014; (special issue):15. (In Russ.)].
(check this in PDF content)
4
Перунова Н.Ю. Клинический случай применения Файкомпы. Эпилепсия и пароксизмальные состояния 2014;(спецвыпуск):9. [Perunova N.Yu. Clinical case of application of Fycompa. Epilepsy and Paroxysmal States 2014;(special issue):9. (In Russ.)].
(check this in PDF content)
5
Biro A., Stephani U., Tarallo T. et al. Effectiveness and tolerability of Perampanel in children and adolescents with refractory epilepsy. Eur J Paediatr Neurol 2013;17 (Suppl 1):S47–8.
(check this in PDF content)
6
Franco V., Crema F., Iudice A. et al. Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res 2013;70(1): 35–40.
(check this in PDF content)
7
French J.A., Krauss G.L., Biton V. et al. Adjunctive perampanel for refractory partialonset seizures: randomized phase III study 304. Neurology 2012;79(6):589–96.
(check this in PDF content)
8
French J.A., Krauss G.L., Steinhoff B.J. et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013;54(1):117–25.
(check this in PDF content)
9
Hanada T. The discovery and development of perampanel for the treatment of epilepsy. Expert Opin Drug Discov 2014;9(4):449–58.
(check this in PDF content)
10
Kerling F., Kasper B.S. Efficacy of perampanel: a review of clinical trial data. Acta Neurol Scand Suppl 2013;(197):25–9.
(check this in PDF content)
11
Ko D., Ramsay R.E. Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures. Acta Neurol Scand Suppl 2013;(197):36–43.
(check this in PDF content)
12
Krauss G.L. Perampanel: a selective AMPA antagonist for treating seizures. Epilepsy Curr 2013;13(6):269–72.
(check this in PDF content)
13
Krauss G.L., Bar M., Biton V. et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 2012;125(1):8–15.
(check this in PDF content)
14
Krauss G.L., Perucca E., Ben-Menachem E. еt al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarilygeneralized seizures: results from phase III extension study 307. Epilepsia 2014;55(7):1058–68.
(check this in PDF content)
15
Krauss G.L., Perucca E., Ben-Menachem E. еt al. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partialonset seizures: interim results from phase III, extension study 307. Epilepsia 2013;54(1): 126–34.
(check this in PDF content)
16
Krauss G.L., Serratosa J.M., Villanueva V. et al. Randomized phase III study 306: adjunctive perampanel for refractory partialonset seizures. Neurology 2012;78(18):1408–15.
(check this in PDF content)
17
Patsalos P.N. Drug interactions with the newer antiepileptic drugs (AEDs) – part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet 2013;52(11):927–66.
(check this in PDF content)
18
Rektor I., Krauss G.L., Bar M. et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand 2012;126(4):263–9.
(check this in PDF content)
19
Rheims S., Ryvlin P. Profile of perampanel and its potential in the treatment of partial onset seizures. Neuropsychiatr Dis Treat 2013;9:629–37.
(check this in PDF content)
20
Rogawski M.A. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Currents 2011:11(2):56–63.
(check this in PDF content)
21
Satlin A., Kramer L.D., Laurenza A. Development of perampanel in epilepsy. Acta Neurol Scand Suppl 2013;(197):3–8.
(check this in PDF content)
22
Shih J.J., Tatum W.O., Rudzinski L.A. New drug classes for the treatment of partial onset 18 RGDN_04_2014 Block.indd 18RGDN_04_2014 Block.indd 1830.12.2014 10:01:1830.12.2014 10:01:18 epilepsy: focus on perampanel. Ther Clin Risk Manag 2013;9:285–93.
(check this in PDF content)
23
Steinhoff B.J. Efficacy of perampanel: a review of pooled data. Epilepsia 2014;55 Suppl 1:9–12.
(check this in PDF content)
24
Steinhoff B.J., Bacher M., Bast T. et al. First clinical experiences with perampanel – the Kork experience in 74 patients. Epilepsia 2014;55 Suppl 1: 16–8.
(check this in PDF content)
25
Steinhoff B.J., Ben-Menachem E., Ryvlin P. et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 2013;54(8):1481–9.
(check this in PDF content)
26
Zwart R., Sher E., Ping X. et al. Perampanel, an аntagonist of α-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid receptors for the treatment of epilepsy: studies in human epileptic brain, nonepi
(check this in PDF content)